Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.

You may also be interested in...



Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens

Leading the way in translation regulation, biotech moves its first candidate into clinical development in solid tumors, but plans quick move also into lymphoma.

Start-Up Quarterly Statistics, Q2 2013

The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.

Biopharma Dealmaking Quarterly Statistics, Q2 2013

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel